Impact of antithrombotic medications on postprocedural outcomes of percutaneous endoscopic gastrostomy: a US Collaborative Network study
Recommended Citation
Elfert K, Abusuliman M, Elbenawi H, Abosheaishaa H, Beran A, Mohamed M, Nassar M, Krafft M, and Elhanafi SE. Impact of antithrombotic medications on postprocedural outcomes of percutaneous endoscopic gastrostomy: a US Collaborative Network study. Eur J Gastroenterol Hepatol 2025.
Document Type
Article
Publication Date
4-29-2025
Publication Title
European journal of gastroenterology & hepatology
Abstract
BACKGROUND AND AIMS: Percutaneous endoscopic gastrostomy (PEG) is an essential procedure for patients who require long-term enteral nutrition but are unable to eat orally. However, it carries a risk of bleeding, particularly in patients on anticoagulation or dual antiplatelet therapy (DAPT). This study aimed to assess the bleeding risk associated with continuing anticoagulation or DAPT during PEG placement.
METHODS: Using the TriNetX US Collaborative Network Database, we analyzed four cohorts: patients on anticoagulants, patients not on anticoagulants, patients on DAPT, and patients on aspirin (ASP), focusing on gastrostomy-related bleeding within 7 and 30 days, along with secondary outcomes such as mortality and the need for blood transfusion or endoscopic reintervention.
RESULTS: Our analysis showed no statistically significant difference in the 7-day bleeding risk between the anticoagulant and no anticoagulant groups. However, a higher 30-day bleeding risk was observed in the anticoagulant group (0.9 vs. 0.4%, P = 0.007). There was no significant difference in the incidence of severe bleeding events requiring endoscopic intervention or blood transfusion. In addition, the difference in the bleeding risk between the DAPT and ASP groups was not statistically significant within 7 and 30 days.
CONCLUSION: These findings suggest that while anticoagulant use increases the risk of minor post-PEG bleeding, it does not lead to a higher incidence of severe bleeding. Additionally, the continuation of DAPT was not associated with statistically significant increase in bleeding risk. This study provides valuable insights into the management of antithrombotic therapy in patients undergoing PEG.
PubMed ID
40359274
ePublication
ePub ahead of print
